DermTech, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DMTK research report →
Companywww.dermtech.com
DermTech, Inc. , a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions.
- CEO
- Bret Christensen
- IPO
- 2017
- Employees
- 206
- HQ
- La Jolla, CA, US
Price Chart
Valuation
- Market Cap
- $3.29M
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -0.18
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 1.80%
- Op Margin
- -678.21%
- Net Margin
- -659.57%
- ROE
- -106.46%
- ROIC
- -92.98%
Growth & Income
- Revenue
- $15.30M · 5.36%
- Net Income
- $-100,888,000 · 13.54%
- EPS
- $-3.09 · 20.36%
- Op Income
- $-103,739,000
- FCF YoY
- 20.99%
Performance & Tape
- 52W High
- $3.90
- 52W Low
- $0.04
- 50D MA
- $0.31
- 200D MA
- $0.97
- Beta
- 2.42
- Avg Volume
- 1.89M
Get TickerSpark's AI analysis on DMTK
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 10, 24 | Sun Kevin M | other | 445 |
| Jun 5, 24 | Akhavan Ramin | other | 1,757 |
| Jun 5, 24 | Akhavan Ramin | other | 1,988 |
| Jun 5, 24 | Sun Kevin M | other | 179 |
| Jun 5, 24 | Sun Kevin M | other | 2,236 |
| Jun 5, 24 | Sun Kevin M | other | 2,530 |
| Mar 10, 24 | Sun Kevin M | other | 445 |
| Mar 5, 24 | Sun Kevin M | other | 0 |
| Mar 5, 24 | Akhavan Ramin | other | 1,758 |
| Mar 5, 24 | Akhavan Ramin | other | 1,989 |
Our DMTK Coverage
We haven't published any research on DMTK yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DMTK Report →